Novavax (NVAX) stock soars 120% as Sanofi deal 'kicks off a new chapter'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
JPMorgan Upgrades Novavax (NVAX) to Neutral, 'Sanofi Licensing Deal Brings In Flu Heavy Weight and Lifts Going Concern'
May 10, 2024 9:27 AM EDTJPMorgan analyst Eric Joseph upgraded Novavax (NASDAQ: NVAX) from Underweight to Neutral.
The analyst comments "On the back of the announced licensing deal with Sanofi, we are upgrading Novavax shares to Neutral from Underweight. With the injection of cash upfront ($500M) removing Novavaxs going concern, , and the greater commercial heft brought to both COVID... More
Novavax (NVAX) Misses Q1 EPS by 13c; offers outlook
May 10, 2024 4:06 AM EDTNovavax (NASDAQ: NVAX) reported Q1 EPS of ($1.05), $0.13 worse than the analyst estimate of ($0.92). Revenue for the quarter came in at $93.85 million versus the consensus estimate of $141.16 million.
GUIDANCE:
Novavax sees FY2024 revenue of $800 million to $1 billion, versus the consensus of $845.5... More
